The availability of comprehensive clinical data sets from the ongoing and planned clinical trials of metabolic inhibitors [72, 74], such as those targeting MCT1, LDHA, and GLUT1, will ultimately enable the clinical assessment of the therapeutic potential of targeting cancer metabolism as proposed in this perspective. This evidence concerns the gene SLC2A1 and cancer.